In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.

Area of Science:

• Pharmacology
• Oncology
• Biocompatibility Testing

Background:

• BIBX1382BS is a novel human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed as an anticancer agent.
• The drug is formulated as a lyophilized product for parenteral administration, requiring investigation into optimal intravenous delivery.
• Low pH of BIBX1382BS solutions necessitates evaluation of hemolytic and precipitation potential.

Purpose of the Study:

• To establish optimal intravenous administration conditions for BIBX1382BS.
• To assess the in vitro hemolytic and precipitation potential of BIBX1382BS infusion solutions.
• To determine the formulation (F) to blood simulans (B) ratio (FB-ratio) for achieving physiological pH.

Main Methods:

• In vitro biocompatibility screening program.
• Evaluation of drug concentration and infusion rate effects on hemolysis and precipitation.
• Determination of the FB-ratio for pH neutralization.

Main Results:

• Optimal infusion concentration for BIBX1382BS is 1 mg/ml.
• Recommended maximum infusion rate is 10 ml/min.
• The study established in vitro biocompatibility parameters for intravenous administration.

Conclusions:

• BIBX1382BS can be safely administered intravenously at 1 mg/ml and a maximum rate of 10 ml/min.
• The in vitro study provides essential data for forthcoming clinical bioavailability studies.
• Understanding in vitro biocompatibility is crucial for optimizing parenteral drug delivery.